Home Newsfeeds Morgan Stanley Maintains Overweight on Samsara, Lowers Price Target to $17

Morgan Stanley Maintains Overweight on Samsara, Lowers Price Target to $17

Morgan Stanley analyst Keith Weiss maintains Samsara (NYSE:IOT) with a Overweight and lowers the price target from $18 to $17.

byBenzinga Newsdesk

November 22, 2022

1 minute read

Morgan Stanley analyst Keith Weiss maintains Samsara (NYSE:IOT) with a Overweight and lowers the price target from $18 to $17.

Apple’s Move To Remove Blood Oxygen Feature In US Watches May Affect Sleep Apnea Detection, Says Mark Gurman

By Ananya Gairola

January 21, 9:50 PM

Apple's removal of the blood oxygen tracking feature from its smartwatches could impact its future health-related capabilities, including sleep apnea detection, as highlighted by Mark Gurman.

AAPL

Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia’s AI Revenues To Reach $300B In Five Years: Today’s Top Stories

By Vandana Singh

July 25, 10:26 AM

The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event

AAL

Ipsen’s Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA

By Benzinga Newsdesk

February 13, 5:50 PM

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and

IPSEY

Price Over Earnings Overview: Cigna Group

By Benzinga Insights

December 28, 11:00 AM

Looking into the current session, Cigna Group Inc. (NYSE:CI) shares are trading at $300.64, after a 0.50% increase.…

Morgan Stanley Maintains Overweight on Samsara, Lowers Price Target to $17

Related Posts

Apple’s Move To Remove Blood Oxygen Feature In US Watches May Affect Sleep Apnea Detection, Says Mark Gurman

Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia’s AI Revenues To Reach $300B In Five Years: Today’s Top Stories

Ipsen’s Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA

Price Over Earnings Overview: Cigna Group